Assessment of Conventional Cardiovascular Risk Factors and Multiple Biomarkers for the Prediction of Incident Heart Failure and Atrial Fibrillation

Overview

Journal J Am Coll Cardiol

Specialty Cardiology & Vascular Diseases

Date 2010 Nov 13

PMID 21070922

Citations 125

Authors

J Gustav Smith

Christopher Newton-Cheh

Peter Almgren

Joachim Struck

Nils G Morgenthaler

Andreas Bergmann

Pyotr G Platonov

Bo Hedblad

Gunnar Engstrom

Thomas J Wang

Olle Melander

Affiliations

Soon will be listed here.

Abstract

Objectives: the purpose of this study was to assess the predictive accuracy of conventional cardiovascular risk factors for incident heart failure and atrial fibrillation, and the added benefit of multiple biomarkers reflecting diverse pathophysiological pathways.

Background: heart failure and atrial fibrillation are interrelated cardiac diseases associated with substantial morbidity and mortality and increasing incidence. Data on prediction and prevention of these diseases in healthy individuals are limited.

Methods: in 5,187 individuals from the community-based MDCS (Malmö Diet and Cancer Study), we studied the performance of conventional risk factors and 6 biomarkers including midregional pro-atrial natriuretic peptide (MR-proANP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-adrenomedullin, cystatin C, C-reactive protein (CRP), and copeptin.

Results: during a mean follow-up of 14 years, 112 individuals were diagnosed with heart failure and 284 individuals with atrial fibrillation. NT-proBNP (hazard ratio [HR]: 1.63 per SD, 95% confidence interval [CI]: 1.29 to 2.06, p < 0.001), CRP (HR: 1.57 per SD, 95% CI: 1.28 to 1.94, p < 0.001), and MR-proANP (HR: 1.26 per SD, 95% CI: 1.02 to 1.56, p = 0.03) predicted incident heart failure independently of conventional risk factors and other biomarkers. MR-proANP (HR: 1.62, 95% CI: 1.42 to 1.84, p < 0.001) and CRP (HR: 1.18, 95% CI: 1.03 to 1.34, p = 0.01) independently predicted atrial fibrillation. Addition of biomarkers to conventional risk factors improved c-statistics from 0.815 to 0.842 for heart failure and from 0.732 to 0.753 for atrial fibrillation and the integrated discrimination improvement for both diseases (p < 0.001). Net reclassification improvement (NRI) with biomarkers was observed in 22% of individuals for heart failure (NRI, p < 0.001) and in 7% for atrial fibrillation (NRI, p = 0.06), mainly due to up-classification of individuals who developed disease (heart failure: 29%, atrial fibrillation: 19%). Addition of CRP to natriuretic peptides did not improve discrimination or reclassification.

Conclusions: conventional cardiovascular risk factors predict incident heart failure and atrial fibrillation with reasonable accuracy in middle-age individuals free from disease. Natriuretic peptides, but not other biomarkers, improve discrimination modestly for both diseases above and beyond conventional risk factors and substantially improve risk classification for heart failure.

Citing Articles

Correlation Between Voltage and Impedance Mapping in Patients with Atrial Fibrillation.

Taormina A, Grossi B, Ragaini E, Falasconi G, Penela D, Ceriotti C J Clin Med. 2025; 14(1.

PMID: 39797213 PMC: 11720856. DOI: 10.3390/jcm14010130.

Lymphocyte to White Blood Cell Count Ratio an Independent Risk Factor for Heart Failure.

Charach L, Spitzer A, Zusmanovitch L, Charach G Life (Basel). 2024; 14(10).

PMID: 39459566 PMC: 11509067. DOI: 10.3390/life14101266.

Comparison of heart failure risk assessment tools among cancer survivors.

Soh C, Marwick T Cardiooncology. 2024; 10(1):67.

PMID: 39394611 PMC: 11468191. DOI: 10.1186/s40959-024-00267-5.

Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population.

Kosyakovsky L, de Boer R, Ho J Curr Heart Fail Rep. 2024; 21(6):591-603.

PMID: 39287754 DOI: 10.1007/s11897-024-00686-6.

Predictive value of NT pro BNP for new-onset atrial fibrillation in heart failure and preserved ejection fraction.

Liu X, Chen S, Pan H, Zhang Z, Wang Y, Jiang Y ESC Heart Fail. 2024; 11(6):4296-4307.

PMID: 39193834 PMC: 11631295. DOI: 10.1002/ehf2.14951.

References

Hammar N, Alfredsson L, Rosen M, Spetz C, Kahan T, Ysberg A . A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol. 2002; 30 Suppl 1:S30-4. DOI: 10.1093/ije/30.suppl_1.s30. View

Wilson P, Smith Jr S, Blumenthal R, Burke G, Wong N . 34th Bethesda Conference: Task force #4--How do we select patients for atherosclerosis imaging?. J Am Coll Cardiol. 2003; 41(11):1898-906. DOI: 10.1016/s0735-1097(03)00361-9. View

Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G . Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009; 302(1):49-57. PMC: 3090639. DOI: 10.1001/jama.2009.943. View

Braunwald E . Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997; 337(19):1360-9. DOI: 10.1056/NEJM199711063371906. View

Roger V, Weston S, Redfield M, Hellermann-Homan J, Killian J, Yawn B . Trends in heart failure incidence and survival in a community-based population. JAMA. 2004; 292(3):344-50. DOI: 10.1001/jama.292.3.344. View

Benjamin E, Chen P, Bild D, Mascette A, Albert C, Alonso A . Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation. 2009; 119(4):606-18. PMC: 2635942. DOI: 10.1161/CIRCULATIONAHA.108.825380. View

Maisel W, Stevenson L . Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003; 91(6A):2D-8D. DOI: 10.1016/s0002-9149(02)03373-8. View

Wang T, Evans J, Benjamin E, Levy D, LeRoy E, Vasan R . Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003; 108(8):977-82. DOI: 10.1161/01.CIR.0000085166.44904.79. View

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F . Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438):937-52. DOI: 10.1016/S0140-6736(04)17018-9. View

10.

Lloyd-Jones D, Wang T, Leip E, Larson M, Levy D, Vasan R . Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004; 110(9):1042-6. DOI: 10.1161/01.CIR.0000140263.20897.42. View

11.

Wang T, Gona P, Larson M, Tofler G, Levy D, Newton-Cheh C . Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006; 355(25):2631-9. DOI: 10.1056/NEJMoa055373. View

12.

Costello-Boerrigter L, Boerrigter G, Redfield M, Rodeheffer R, Urban L, Mahoney D . Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006; 47(2):345-53. PMC: 2647136. DOI: 10.1016/j.jacc.2005.09.025. View

13.

Cook N . Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007; 115(7):928-35. DOI: 10.1161/CIRCULATIONAHA.106.672402. View

14.

Tschope C, Kasner M, Westermann D, Gaub R, Poller W, Schultheiss H . The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005; 26(21):2277-84. DOI: 10.1093/eurheartj/ehi406. View

15.

Pencina M, DAgostino Sr R, DAgostino Jr R, Vasan R . Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2007; 27(2):157-72. DOI: 10.1002/sim.2929. View

16.

Yusuf S, Pitt B, Davis C, Hood W, Cohn J . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325(5):293-302. DOI: 10.1056/NEJM199108013250501. View

17.

Butler J, Kalogeropoulos A, Georgiopoulou V, BeLue R, Rodondi N, Garcia M . Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail. 2009; 1(2):125-33. PMC: 2748334. DOI: 10.1161/CIRCHEARTFAILURE.108.768457. View

18.

Kannel W, Belanger A . Epidemiology of heart failure. Am Heart J. 1991; 121(3 Pt 1):951-7. DOI: 10.1016/0002-8703(91)90225-7. View

19.

Ingelsson E, Arnlov J, Sundstrom J, Lind L . The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail. 2005; 7(5):787-91. DOI: 10.1016/j.ejheart.2004.12.007. View

20.

Danesh J, Wheeler J, Hirschfield G, Eda S, Eiriksdottir G, Rumley A . C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350(14):1387-97. DOI: 10.1056/NEJMoa032804. View